Your browser is no longer supported. Please, upgrade your browser.
ADPT Adaptive Biotechnologies Corporation weekly Stock Chart
ADPT [NASD]
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-0.95 Insider Own1.30% Shs Outstand134.37M Perf Week-1.86%
Market Cap6.15B Forward P/E- EPS next Y-1.15 Insider Trans-82.55% Shs Float128.88M Perf Month-7.41%
Income-122.30M PEG- EPS next Q-0.29 Inst Own82.10% Short Float3.72% Perf Quarter9.59%
Sales92.40M P/S66.54 EPS this Y-42.00% Inst Trans9.59% Short Ratio5.53 Perf Half Y17.27%
Book/sh5.77 P/B7.94 EPS next Y-6.50% ROA-13.10% Target Price58.17 Perf Year60.02%
Cash/sh6.23 P/C7.36 EPS next 5Y2.20% ROE-20.10% 52W Range15.19 - 54.20 Perf YTD53.18%
Dividend- P/FCF- EPS past 5Y- ROI-12.90% 52W High-15.44% Beta-
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin75.90% 52W Low201.71% ATR3.01
Employees453 Current Ratio8.70 Sales Q/Q0.80% Oper. Margin- RSI (14)44.51 Volatility7.06% 6.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-143.60% Profit Margin- Rel Volume0.64 Prev Close46.40
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume866.39K Price45.83
Recom1.60 SMA20-5.91% SMA50-5.83% SMA20017.95% Volume552,081 Change-1.23%
Oct-08-20Resumed BTIG Research Buy $60
Sep-09-20Initiated Morgan Stanley Equal-Weight $42
Jun-03-20Initiated Goldman Buy $60
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Nov-23-20 08:00AM  
Nov-19-20 06:32AM  
Nov-13-20 08:00AM  
Nov-11-20 05:21AM  
05:00AM  
Nov-10-20 05:25PM  
05:22PM  
04:13PM  
04:10PM  
Nov-03-20 12:30PM  
Oct-28-20 05:30PM  
Oct-13-20 04:05PM  
Sep-28-20 10:52AM  
Sep-01-20 04:03PM  
Aug-11-20 01:01AM  
Aug-10-20 06:35PM  
04:05PM  
12:44PM  
08:05AM  
Aug-06-20 09:24AM  
Aug-04-20 09:30AM  
Jul-30-20 06:19AM  
Jul-28-20 06:04PM  
Jul-16-20 12:00PM  
Jul-15-20 07:47PM  
Jul-14-20 04:44PM  
Jul-09-20 04:29PM  
08:05AM  
Jun-23-20 11:54AM  
Jun-17-20 08:56AM  
Jun-15-20 10:27AM  
Jun-11-20 09:00AM  
Jun-08-20 04:03PM  
Jun-07-20 06:25AM  
May-27-20 04:03PM  
May-19-20 08:03AM  
May-18-20 02:47PM  
May-14-20 11:51AM  
May-13-20 12:31PM  
07:02AM  
May-12-20 04:03PM  
08:06AM  
May-11-20 10:57AM  
09:57AM  
May-08-20 09:09AM  
May-06-20 03:06PM  
02:50PM  
12:10PM  
08:19AM  
08:00AM  
May-05-20 12:00PM  
Apr-30-20 08:51AM  
06:39AM  
Apr-27-20 04:03PM  
Apr-20-20 08:15AM  
Apr-17-20 09:13PM  
12:40PM  
Apr-15-20 04:47PM  
08:26AM  
Apr-09-20 07:45PM  
Apr-07-20 08:35PM  
Apr-05-20 10:14AM  
Apr-03-20 10:51AM  
Apr-02-20 07:58PM  
05:50PM  
04:23PM  
04:04PM  
12:29PM  
09:34AM  
09:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:45PM  
Mar-23-20 11:06AM  
Mar-20-20 02:00PM  
01:02PM  
Feb-29-20 07:12AM  
Feb-27-20 05:54PM  
Feb-26-20 04:05PM  
Feb-21-20 10:20AM  
Feb-19-20 04:05PM  
Feb-12-20 04:05PM  
Feb-10-20 08:44AM  
Feb-03-20 11:27AM  
Jan-31-20 11:52AM  
Jan-29-20 09:50AM  
Jan-23-20 08:53PM  
Jan-22-20 08:25AM  
Jan-21-20 04:39PM  
04:02PM  
Jan-13-20 07:30AM  
Jan-08-20 07:30AM  
Dec-30-19 04:05PM  
10:04AM  
Dec-26-19 02:47PM  
Dec-20-19 04:17PM  
Dec-16-19 09:24PM  
Dec-13-19 04:52AM  
Dec-09-19 08:44AM  
08:00AM  
Dec-04-19 04:30PM  
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBINS CHAD MCEO and ChairmanNov 19Option Exercise0.3316,6805,5041,794,860Nov 19 09:00 PM
BENZENO SHARONChief Business Development OffNov 19Option Exercise6.274162,608416Nov 23 06:05 AM
ROBINS CHAD MCEO and ChairmanNov 19Sale46.5716,680776,7411,778,180Nov 19 09:00 PM
BENZENO SHARONChief Business Development OffNov 19Sale48.8641620,3260Nov 23 06:05 AM
ROBINS CHAD MCEO and ChairmanNov 18Option Exercise0.3316,6805,5041,794,860Nov 19 09:00 PM
ROBINS CHAD MCEO and ChairmanNov 18Sale48.2816,680805,3461,778,180Nov 19 09:00 PM
ROBINS CHAD MCEO and ChairmanNov 17Option Exercise0.3316,6805,5041,794,860Nov 19 09:00 PM
ROBINS CHAD MCEO and ChairmanNov 17Sale46.1216,680769,3431,778,180Nov 19 09:00 PM
GRIFFIN MICHELLE RENEEDirectorNov 16Option Exercise7.806,00046,8006,000Nov 18 09:00 PM
HERSHBERG ROBERTDirectorNov 16Option Exercise0.452,0009002,000Nov 18 09:00 PM
LO FRANCISChief People OfficerNov 16Option Exercise7.802,00015,6002,000Nov 18 09:00 PM
GRIFFIN MICHELLE RENEEDirectorNov 16Sale47.696,000286,1350Nov 18 09:00 PM
HERSHBERG ROBERTDirectorNov 16Sale47.692,00095,3810Nov 18 09:00 PM
LO FRANCISChief People OfficerNov 16Sale47.682,00095,3510Nov 18 09:00 PM
VIKING GLOBAL PERFORMANCE LLC10% OwnerNov 11Sale49.522,500,000123,787,50030,993,708Nov 13 09:00 PM
VIKING GLOBAL INVESTORS LP10% OwnerNov 11Sale49.522,500,000123,787,50030,993,708Nov 13 09:01 PM
Cohen Chad MChief Financial OfficerNov 09Option Exercise6.3230,000189,60031,000Nov 12 09:00 PM
Cohen Chad MChief Financial OfficerNov 09Sale49.1630,0001,474,7051,000Nov 12 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 06Option Exercise6.3211,10070,15211,779Nov 06 09:00 PM
BALDO LANCEChief Medical OfficerNov 06Option Exercise7.806,25048,7506,250Nov 10 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 06Sale51.5011,100571,629679Nov 06 09:00 PM
BALDO LANCEChief Medical OfficerNov 06Sale50.636,250316,4490Nov 10 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 05Option Exercise6.3211,10070,15211,779Nov 06 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 05Sale50.3011,100558,384679Nov 06 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 04Option Exercise6.3211,10070,15211,779Nov 06 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 04Sale50.2911,100558,234679Nov 06 09:00 PM
BENZENO SHARONChief Business Development OffNov 02Option Exercise6.726,77245,4826,772Nov 04 07:00 PM
BENZENO SHARONChief Business Development OffNov 02Sale45.586,772308,6420Nov 04 07:00 PM
Taylor Stacy LSVP and General CounselOct 26Option Exercise7.032,88020,2524,180Oct 28 07:00 PM
Taylor Stacy LSVP and General CounselOct 26Sale49.782,880143,3601,300Oct 28 07:00 PM
BENZENO SHARONChief Business Development OffOct 19Option Exercise6.274172,615417Oct 20 07:00 PM
BENZENO SHARONChief Business Development OffOct 19Sale51.2541721,3710Oct 20 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 16Option Exercise6.3211,10070,15211,779Oct 20 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 16Sale51.7911,100574,869679Oct 20 07:00 PM
HERSHBERG ROBERTDirectorOct 15Option Exercise0.452,0009002,000Oct 16 05:00 PM
LO FRANCISChief People OfficerOct 15Option Exercise7.802,00015,6002,000Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 15Option Exercise6.3211,10070,15211,779Oct 16 05:00 PM
HERSHBERG ROBERTDirectorOct 15Sale51.512,000103,0200Oct 16 05:00 PM
LO FRANCISChief People OfficerOct 15Sale51.512,000103,0200Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 15Sale51.5511,100572,205679Oct 16 05:00 PM
Pellini Michael JDirectorOct 14Option Exercise6.5550,000327,50050,000Oct 16 05:00 PM
GRIFFIN MICHELLE RENEEDirectorOct 14Option Exercise7.8012,00093,60012,000Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 14Option Exercise6.3211,10070,15211,779Oct 16 05:00 PM
Pellini Michael JDirectorOct 14Sale52.3550,0002,617,5500Oct 16 05:00 PM
GRIFFIN MICHELLE RENEEDirectorOct 14Sale52.8412,000634,0970Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 14Sale52.1711,100579,133679Oct 16 05:00 PM
LO FRANCISChief People OfficerOct 12Option Exercise7.8025,000195,00025,000Oct 14 09:00 PM
LO FRANCISChief People OfficerOct 12Sale52.8025,0001,320,0000Oct 14 09:00 PM
ROBINS CHAD MCEO and ChairmanOct 08Option Exercise0.3324,2608,0061,802,440Oct 08 07:26 PM
Cohen Chad MChief Financial OfficerOct 08Option Exercise6.3230,000189,60031,000Oct 08 07:24 PM
Cohen Chad MChief Financial OfficerOct 08Sale50.6530,0001,519,4291,000Oct 08 07:24 PM
ROBINS CHAD MCEO and ChairmanOct 08Sale50.6124,2601,227,7201,778,180Oct 08 07:26 PM
ROBINS CHAD MCEO and ChairmanOct 07Option Exercise0.3350,00016,5001,828,180Oct 08 07:26 PM
ROBINS CHAD MCEO and ChairmanOct 07Sale50.1850,0002,509,0401,778,180Oct 08 07:26 PM
ROBINS CHAD MCEO and ChairmanOct 06Option Exercise0.3318,2806,0321,796,460Oct 08 07:26 PM
BALDO LANCEChief Medical OfficerOct 06Option Exercise7.806,25048,7506,250Oct 07 07:00 PM
ROBINS CHAD MCEO and ChairmanOct 06Sale49.3618,280902,3431,778,180Oct 08 07:26 PM
BALDO LANCEChief Medical OfficerOct 06Sale49.206,250307,5180Oct 07 07:00 PM
BENZENO SHARONChief Business Development OffOct 01Option Exercise6.726,77145,4756,771Oct 02 07:00 PM
DOBMEIER ERICDirectorOct 01Option Exercise6.3210,00063,20010,000Oct 02 07:00 PM
RUBINSTEIN JULIEPresidentOct 01Option Exercise0.8414,72512,36914,725Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanOct 01Option Exercise0.336001981,778,780Oct 01 08:00 PM
BENZENO SHARONChief Business Development OffOct 01Sale48.576,771328,8370Oct 02 07:00 PM
DOBMEIER ERICDirectorOct 01Sale48.5310,000485,2740Oct 02 07:00 PM
RUBINSTEIN JULIEPresidentOct 01Sale49.0014,725721,5250Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanOct 01Sale50.0560030,0301,778,180Oct 01 08:00 PM
RUBINSTEIN JULIEPresidentSep 29Option Exercise0.8480,00067,20080,000Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanSep 29Option Exercise0.331,9006271,780,080Oct 01 08:00 PM
BALDO LANCEChief Medical OfficerSep 29Option Exercise7.8025,000195,00025,000Oct 01 08:00 PM
BOBULSKY SUSANSVP, Diagnostics, clonoSEQSep 29Option Exercise1.9810,00019,80010,000Oct 01 08:00 PM
RUBINSTEIN JULIEPresidentSep 29Sale49.0080,0003,920,0000Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanSep 29Sale50.181,90095,3421,778,180Oct 01 08:00 PM
BALDO LANCEChief Medical OfficerSep 29Sale50.0025,0001,250,0000Oct 01 08:00 PM
BOBULSKY SUSANSVP, Diagnostics, clonoSEQSep 29Sale50.0010,000500,0000Oct 01 08:00 PM
Taylor Stacy LSVP and General CounselSep 24Option Exercise7.032,88020,2504,180Sep 28 08:00 PM
ROBINS HARLAN SChief Scientific OfficerSep 24Option Exercise6.3211,10070,15211,779Sep 24 08:24 PM
Taylor Stacy LSVP and General CounselSep 24Sale47.782,880137,5961,300Sep 28 08:00 PM
ROBINS HARLAN SChief Scientific OfficerSep 24Sale47.1111,100522,879679Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 23Option Exercise6.3211,10070,15211,779Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 23Sale48.1611,100534,576679Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 22Option Exercise6.3211,10070,15211,779Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 22Sale47.5711,100527,975679Sep 24 08:24 PM
BENZENO SHARONChief Business Development OffSep 21Option Exercise6.274172,615417Sep 23 08:00 PM
BENZENO SHARONChief Business Development OffSep 21Sale45.5141718,9780Sep 23 08:00 PM
ROBINS CHAD MCEO and ChairmanSep 18Option Exercise0.3316,6805,5041,794,860Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 18Sale45.7216,680762,5631,778,180Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 17Option Exercise0.3316,6805,5041,794,860Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 17Sale45.1416,680752,9091,778,180Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 16Option Exercise0.3316,6805,5041,794,860Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 16Sale46.4416,680774,6051,738,680Sep 18 09:00 PM
HERSHBERG ROBERTDirectorSep 15Option Exercise0.452,0009002,000Sep 16 09:00 PM
LO FRANCISChief People OfficerSep 15Option Exercise7.802,00015,6002,000Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 15Option Exercise6.3225,000158,00025,000Sep 16 09:00 PM
HERSHBERG ROBERTDirectorSep 15Sale42.582,00085,1600Sep 16 09:00 PM
LO FRANCISChief People OfficerSep 15Sale42.582,00085,1600Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 15Sale44.0025,0001,100,0000Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 14Option Exercise6.5525,000163,75025,000Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 14Sale42.5025,0001,062,5000Sep 16 09:00 PM
Cohen Chad MChief Financial OfficerSep 11Option Exercise6.328,58854,2769,588Sep 11 09:00 PM
BALDO LANCEChief Medical OfficerSep 11Option Exercise7.804,14932,3624,149Sep 11 09:00 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.